282 related articles for article (PubMed ID: 32780094)
1. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Lin A; Roth H; Anyane-Yeboa A; Rubin DT; Paul S
Inflamm Bowel Dis; 2021 May; 27(6):947-955. PubMed ID: 32780094
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.
Zou ZY; Shen B; Fan JG
Inflamm Bowel Dis; 2019 Oct; 25(11):1764-1772. PubMed ID: 30918952
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
Zamani M; Alizadeh-Tabari S; Singh S; Loomba R
Aliment Pharmacol Ther; 2022 Apr; 55(8):894-907. PubMed ID: 35274325
[TBL] [Abstract][Full Text] [Related]
4. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis.
Lapumnuaypol K; Kanjanahattakij N; Pisarcik D; Thongprayoon C; Wijarnpreecha K; Cheungpasitporn W
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):854-860. PubMed ID: 29697458
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.
Abenavoli L; Spagnuolo R; Scarlata GGM; Scarpellini E; Boccuto L; Luzza F
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003983
[No Abstract] [Full Text] [Related]
6. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease.
Bosch DE; Yeh MM
Hum Pathol; 2017 Nov; 69():55-62. PubMed ID: 28970141
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.
Magrì S; Paduano D; Chicco F; Cingolani A; Farris C; Delogu G; Tumbarello F; Lai M; Melis A; Casula L; Fantini MC; Usai P
World J Gastroenterol; 2019 Oct; 25(37):5676-5686. PubMed ID: 31602167
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors.
Principi M; Iannone A; Losurdo G; Mangia M; Shahini E; Albano F; Rizzi SF; La Fortezza RF; Lovero R; Contaldo A; Barone M; Leandro G; Ierardi E; Di Leo A
Inflamm Bowel Dis; 2018 Jun; 24(7):1589-1596. PubMed ID: 29688336
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease.
Kang MK; Kim KO; Kim MC; Park JG; Jang BI
Dig Dis; 2020; 38(6):507-514. PubMed ID: 32135539
[TBL] [Abstract][Full Text] [Related]
10. Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.
Martínez-Domínguez SJ; García-Mateo S; Gargallo-Puyuelo CJ; Gallego Llera B; Refaie E; Callau P; Mendi C; Baptista PM; Hernández Ainsa M; Arroyo-Villarino MT; López de la Cruz J; Martínez-García J; Alfambra E; Simón Marco MÁ; Ampuero J; Gomollón F
Eur J Intern Med; 2024 Feb; 120():99-106. PubMed ID: 37872034
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
Yen HH; Su PY; Huang SP; Wu L; Hsu TC; Zeng YH; Chen YY
PLoS One; 2021; 16(5):e0252286. PubMed ID: 34043691
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
[TBL] [Abstract][Full Text] [Related]
13. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis.
Noorian S; Jeon Y; Nguyen MT; Sauk J; Limketkai BN
Inflamm Bowel Dis; 2022 Jun; 28(6):878-887. PubMed ID: 34374782
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease.
Navarro P; Gutiérrez-Ramírez L; Tejera-Muñoz A; Arias Á; Lucendo AJ
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960160
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis.
Hoffmann P; Jung V; Behnisch R; Gauss A
World J Gastroenterol; 2020 Dec; 26(46):7367-7381. PubMed ID: 33362390
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.
Glassner K; Malaty HM; Abraham BP
Inflamm Bowel Dis; 2017 Jun; 23(6):998-1003. PubMed ID: 28511199
[TBL] [Abstract][Full Text] [Related]
17. The evaluation of liver abnormalities in inflammatory bowel disease patients.
McHenry S
Curr Opin Gastroenterol; 2023 Jul; 39(4):287-293. PubMed ID: 37144524
[TBL] [Abstract][Full Text] [Related]
18. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
[TBL] [Abstract][Full Text] [Related]
19. Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-analysis.
Trivedi HD; Lopes EW; Glissen Brown J; Dudani S; Lai M; Feuerstein JD; Pierce TT
J Clin Gastroenterol; 2023 Jul; 57(6):610-616. PubMed ID: 35648974
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease.
Hyun HK; Lee HW; Park J; Park SJ; Park JJ; Kim TI; Lee JS; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU; Cheon JH
Gut Liver; 2024 Mar; 18(2):294-304. PubMed ID: 37203442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
